Evaluation of Broadband Light Treatment Protocol for Pigmented Skin Lesions - A Comparative Study
1 other identifier
interventional
3
1 country
1
Brief Summary
Evaluation of Broadband Light Treatment Protocols for Pigmented Skin Lesions - A comparative study
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2022
CompletedFirst Submitted
Initial submission to the registry
December 6, 2022
CompletedFirst Posted
Study publicly available on registry
December 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 6, 2023
CompletedDecember 1, 2023
November 1, 2023
8 months
December 6, 2022
November 29, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Change in pigmentation, skin tone and texture
Change in pigmentation, skin tone and texture will be evaluated using photographs captured at baseline and 4-6 weeks post treatment
4-6 weeks
Study Arms (1)
Treatment Arm
EXPERIMENTALBroadband light treatment will be provided on pigmented skin lesions
Interventions
Broadband Light device will be used for treatment of pigmented skin lesions
Eligibility Criteria
You may qualify if:
- Healthy male or female, 18 years or older
- Fitzpatrick skin type I-IV
- Has visible signs of moderate to severe skin pigmentation
- Willing to not use any other procedure(s) in the treatment area during the study, such as laser- or light-based treatment, non-light-based device treatment such as radiofrequency or ultrasound, injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler, chemical peel, or surgical procedure
- Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study. (applicable to female subjects only)
- Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period
- Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes
- Subject must agree to not make any changes in their skin regimen for the duration of the study, including the follow-up period
- Subject must be able to read, understand and sign Informed Consent Form
- Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions
You may not qualify if:
- Fitzpatrick skin type V-VI
- Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.
- Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser or light-based procedures or surgery.
- Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler in the target area within 1 week of study participation.
- History of malignant tumors in the target area.
- Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
- Pregnant and/or breastfeeding (applicable to female subjects only)
- Having an infection, dermatitis or a rash in the treatment area.
- Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
- Suffering from coagulation disorders or taking prescription anticoagulation medications.
- History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- History of vitiligo, eczema, or psoriasis.
- History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
- History of seizure disorders due to light.
- +10 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Scitonlead
Study Sites (1)
New Jersey Plastic Surgery
Montclair, New Jersey, 07042, United States
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 6, 2022
First Posted
December 22, 2022
Study Start
October 1, 2022
Primary Completion
May 30, 2023
Study Completion
June 6, 2023
Last Updated
December 1, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share